Acne VulgarisCXCL10NCT06869109
Serum CXCL10 and CRP Levels in Patients With Acne Vulgaris in Correlation With Disease Severity
An observational study of Acne Vulgaris, run by Assiut University at 1 site in Egypt.
Trial summary
the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Read more about this study
- Who is it for?
- Ages 12 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Acne Vulgaris
- What is being tested?
- serum cxcl10 and serum crp
- How many people
- 88 participants
- Where
- 1 siteEgypt
- Study dates
- 10 Mar 2025to 10 Apr 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 40 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: the patients with acne with different severity
Who may be able to join
- Patients aged 12-40 years diagnosed with acne vulgaris.
- Both genders included.
- Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
- Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.
Who cannot join
- Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
- Pregnant or lactating individuals.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Understanding the relationship between CXCL10, CRP, and acne severity may offer insights into novel therapeutic strategies targeting inflammatory pathways in acne.
Read the detailed description
Cross-sectional Observational Study. using 4 groups a 3 of different acne severity and controle one . the serum cxcl10 and crp will measured in each patient to correlate with disease severity
- Conditions
- Acne Vulgaris
- Being tested
- serum cxcl10, serum crp
- Keywords
- acne vulgaris, cxcl10, crp
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
serum cxcl10Diagnostic test
serum blood sample to measure the cxcl10
serum crpDiagnostic test
blood sample to measure crp
| Study group | Role | What they receive |
|---|---|---|
| mild acne group | mild disease severity Receives: Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp | |
| moderate acne group | moderate disease severity Receives: Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp | |
| severe acne group | severe disease severity Receives: Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp | |
| control group | healthy people Receives: Diagnostic Test: serum cxcl10; Diagnostic Test: serum crp |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation of CXCL10 and CRP levels with acne severity (GAG score).
compare the result of serum cxcl10 and crp with disease severity
Measured: within one year after the result
Secondary outcomes (2)
Identify thresholds of CXCL10 and CRP for predicting moderate/severe acne
the least result to identify the group
Measured: within one year after the result
Explore potential differences based on sex or age groups
the effect of age and sex on the result
Measured: within one year of the result
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2025
- Study start10 Mar 2025 (estimated)
- Primary completion10 Mar 2026 (estimated)
- Study completion10 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Acne VulgarisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dina Essam, Assiut University
- Investigators
- Doaa Samir, prof, Study director, Assiut UniversityAhmed Shawky, prof, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06869109
- Sponsor's protocol ID
- role of CXCL10 and CRP in acne
- Acronym
- CXCL10
- Status last verified
- Mar 2025
- First submitted
- 4 Mar 2025
- Last updated
- 11 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Abdelrazik YT, Ali FM, Salek MS, Finlay AY. Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI). Br J Dermatol. 2021 Oct;185(4):711-724. doi: 10.1111/bjd.20391. Epub 2021 Jul 22.
PubMed 33864247Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of Acne Vulgaris: Comparison of Two Assessment Methods. Clin Cosmet Investig Dermatol. 2020 Sep 28;13:711-716. doi: 10.2147/CCID.S266320. eCollection 2020.
PubMed 33061511Stańkowska A, Bergler-Czop B, Brzezińska-Wcisło L. Interleukins-6, -8 and -12p40 and C-reactive protein levels in patients with acne vulgaris with various severityof skin changes. Dermatology Review/Przegląd Dermatologiczny. 2020;107(4):308-22
Yang CC, Huang YT, Yu CH, Wu MC, Hsu CC, Chen W. Inflammatory facial acne during uncomplicated pregnancy and post-partum in adult women: a preliminary hospital-based prospective observational study of 35 cases from Taiwan. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1787-1789. doi: 10.1111/jdv.13667. Epub 2016 Apr 22.
PubMed 27102946Kutlu O, Karadag AS, Unal E, Kelekci KH, Yalcinkaya Iyidal A, Topaloglu Demir F, Aksoy B, Colgecen E, Tosun M, Emre S, Tatliparmak A, Demirseren DD, Kaya Ozden H, Ozturk M, Ozlu E, Chen W. Acne in pregnancy: A prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020 Sep;59(9):1098-1105. doi: 10.1111/ijd.14999. Epub 2020 Jun 20.
PubMed 32562263Ansar W, Ghosh S, Ansar W, Ghosh S. Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C reactive protein in health and disease. 2016:67-107
Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86. doi: 10.1002/hep.1840120517.
PubMed 1699862Yu H, Zhang B, Zhan Y, Yi Y, Jiang Q, Zhang Q, Wu Y, Wu M. Neutrophil extracellular trap-related mechanisms in acne vulgaris inspire a novel treatment strategy with adipose-derived stem cells. Sci Rep. 2024 Jan 17;14(1):1521. doi: 10.1038/s41598-024-51931-w.
PubMed 38233540Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis. 2010 Dec 9;9:141. doi: 10.1186/1476-511X-9-141.
PubMed 21143923Jin Z, Song Y, He L. A review of skin immune processes in acne. Front Immunol. 2023 Dec 15;14:1324930. doi: 10.3389/fimmu.2023.1324930. eCollection 2023.
PubMed 38193084Liang J, Chen Y, Wang Z, Wang Y, Mu S, Zhang D, Wang Z, Zeng W. Exploring the association between rosacea and acne by integrated bioinformatics analysis. Sci Rep. 2024 Feb 6;14(1):3065. doi: 10.1038/s41598-024-53453-x.
PubMed 38321132Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29.
PubMed 21880356
Study at a glance
From the registry record, last updated by the sponsor on 11 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum CXCL10 and CRP Levels in Patients With Acne Vulgaris in Correlation With Disease Severity
- ClinicalTrials.gov ID
- NCT06869109
- Acronym / sponsor ID
- CXCL10 / role of CXCL10 and CRP in acne
- Conditions
- Acne Vulgaris
- Keywords
- acne vulgaris, cxcl10, crp
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 10 Mar 2025 (estimated)
- Primary completion
- 10 Mar 2026 (estimated)
- Study completion
- 10 Apr 2026 (estimated)
- First posted
- 11 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the correlations between CXCL10 levels, CRP, and acne severity scores (e.g., Global Acne Grading System) suggest that CXCL10 could serve as a biomarker of inflammation and acne severity. Understanding the relationship between CXCL10, CRP, and acne severity may offer insights into novel therapeutic strategies targeting inflammatory pathways in acne.
Detailed description
Cross-sectional Observational Study. using 4 groups a 3 of different acne severity and controle one . the serum cxcl10 and crp will measured in each patient to correlate with disease severity
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| mild acne group | – | Diagnostic Test: serum cxcl10, Diagnostic Test: serum crpmild disease severity |
| moderate acne group | – | Diagnostic Test: serum cxcl10, Diagnostic Test: serum crpmoderate disease severity |
| severe acne group | – | Diagnostic Test: serum cxcl10, Diagnostic Test: serum crpsevere disease severity |
| control group | – | Diagnostic Test: serum cxcl10, Diagnostic Test: serum crphealthy people |
Who may qualify
- Ages
- 12 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- the patients with acne with different severity
Key inclusion criteria (4 listed)
- Patients aged 12-40 years diagnosed with acne vulgaris.
- Both genders included.
- Patients with mild, moderate, or severe acne severity as determined by a validated scoring system (e.g., Global Acne Grading System).
- Patients not on systemic acne treatment (e.g., isotretinoin or antibiotics) or anti-inflammatory drugs.
Key exclusion criteria (2 listed)
- Patients with autoimmune diseases, systemic illnesses, acute infection or any other chronic inflammatory conditions that may affect CRP or CXCL10 levels.
- Pregnant or lactating individuals.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| serum cxcl10serum blood sample to measure the cxcl10 | Diagnostic test | control group, mild acne group, moderate acne group, severe acne group |
| serum crpblood sample to measure crp | Diagnostic test | control group, mild acne group, moderate acne group, severe acne group |
Primary outcome
Correlation of CXCL10 and CRP levels with acne severity (GAG score).
Time frame: within one year after the result
compare the result of serum cxcl10 and crp with disease severity
2 secondary outcomes
Identify thresholds of CXCL10 and CRP for predicting moderate/severe acne
Time frame: within one year after the result
Explore potential differences based on sex or age groups
Time frame: within one year of the result
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Mar 2025.
- Results publication: PubMed 33864247Abdelrazik YT, Ali FM, Salek MS, Finlay AY. Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI). Br J Dermatol. 2021 Oct;185(4):711-724. doi: 10.1111/bjd.20391. Epub 2021 Jul 22.
- Results publication: PubMed 33061511Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of Acne Vulgaris: Comparison of Two Assessment Methods. Clin Cosmet Investig Dermatol. 2020 Sep 28;13:711-716. doi: 10.2147/CCID.S266320. eCollection 2020.
- Results publicationStańkowska A, Bergler-Czop B, Brzezińska-Wcisło L. Interleukins-6, -8 and -12p40 and C-reactive protein levels in patients with acne vulgaris with various severityof skin changes. Dermatology Review/Przegląd Dermatologiczny. 2020;107(4):308-22
- Results publication: PubMed 27102946Yang CC, Huang YT, Yu CH, Wu MC, Hsu CC, Chen W. Inflammatory facial acne during uncomplicated pregnancy and post-partum in adult women: a preliminary hospital-based prospective observational study of 35 cases from Taiwan. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1787-1789. doi: 10.1111/jdv.13667. Epub 2016 Apr 22.
- Results publication: PubMed 32562263Kutlu O, Karadag AS, Unal E, Kelekci KH, Yalcinkaya Iyidal A, Topaloglu Demir F, Aksoy B, Colgecen E, Tosun M, Emre S, Tatliparmak A, Demirseren DD, Kaya Ozden H, Ozturk M, Ozlu E, Chen W. Acne in pregnancy: A prospective multicenter, cross-sectional study of 295 patients in Turkey. Int J Dermatol. 2020 Sep;59(9):1098-1105. doi: 10.1111/ijd.14999. Epub 2020 Jun 20.
- Results publicationAnsar W, Ghosh S, Ansar W, Ghosh S. Inflammation and inflammatory diseases, markers, and mediators: role of CRP in some inflammatory diseases. Biology of C reactive protein in health and disease. 2016:67-107
- Results publication: PubMed 1699862Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86. doi: 10.1002/hep.1840120517.
- Results publication: PubMed 38233540Yu H, Zhang B, Zhan Y, Yi Y, Jiang Q, Zhang Q, Wu Y, Wu M. Neutrophil extracellular trap-related mechanisms in acne vulgaris inspire a novel treatment strategy with adipose-derived stem cells. Sci Rep. 2024 Jan 17;14(1):1521. doi: 10.1038/s41598-024-51931-w.
- Results publication: PubMed 21143923Bowe WP, Logan AC. Clinical implications of lipid peroxidation in acne vulgaris: old wine in new bottles. Lipids Health Dis. 2010 Dec 9;9:141. doi: 10.1186/1476-511X-9-141.
- Results publication: PubMed 38193084Jin Z, Song Y, He L. A review of skin immune processes in acne. Front Immunol. 2023 Dec 15;14:1324930. doi: 10.3389/fimmu.2023.1324930. eCollection 2023.
- Results publication: PubMed 38321132Liang J, Chen Y, Wang Z, Wang Y, Mu S, Zhang D, Wang Z, Zeng W. Exploring the association between rosacea and acne by integrated bioinformatics analysis. Sci Rep. 2024 Feb 6;14(1):3065. doi: 10.1038/s41598-024-53453-x.
- Results publication: PubMed 21880356Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29.
- Individual participant dataSharing planned: Undecided
Related trials for Acne Vulgaris
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
Hair Reduction, Tattoo Removal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Doaa Samir, prof study director
Assiut University
Ahmed Shawky, prof study director
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acne Vulgaris, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dina Essam, physician (+201027664829, dina.14224214@med.aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation of CXCL10 and CRP levels with acne severity (GAG score). (time frame: within one year after the result). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06869109, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Mar 2025.